Circulating angiotensin converting enzyme 2 activity as a biomarker of silent atherosclerosis in patients with chronic kidney disease
Soler, María José
MetadataShow full item record
Abstract BACKGROUND AND AIMS: Circulating Angiotensin Converting Enzyme 2 (ACE2) activity in chronic kidney disease (CKD) patients without previous history of cardiovascular disease (CVD) has been associated with classical risk factors (older age, diabetes and male gender). Furthermore, silent atherosclerosis
has been described as a pathological link between CKD and CVD. We analyzed baseline ACE2 activity in non-dialysis CKD stages 3-5 (CKD3-5) patients as a biomarker of renal progression, silent atherosclerosis and CV events after 2 years of follow-up. METHODS: Prospective study of 1458 CKD3-5 subjects without any previous CV event included in the Spanish multicenter NEFRONA study. Association between baseline circulating ACE2 activity and renal parameters, carotid/femoral echography, atheromatous disease, ankle-brachial index, intima-media thickness, need of renal replacement therapy, cardiovascular events and mortality at 24 months of follow-up were analyzed. RESULTS: Patients with an increase in the number of territories with plaques at 24 months showed significantly higher levels of baseline ACE2 activity as compared to stable patients (29.6 (20.6-47.6)RFU/μL/h versus 35.7 (24.5-56), p < 0.001). Multivariate linear regression analysis showed that male gender, pathological ankle-brachial index and progressive silent atherosclerosis defined as an increased number of territories with plaques at 24 months were associated with increased baseline ACE2 activity. Male gender, older age, diabetes, smoking and increased baseline circulating ACE2 were independent predictors of atherosclerosis at 24 months of follow-up. CONCLUSIONS: In CKD3-5 patients, higher circulating ACE2 activity at baseline is associated with higher risk for silent atherosclerosis, suggesting that ACE2 may serve as a biomarker to predict CV risk before CVD is established.
Is part ofAtherosclerosis, 2016, vol. 253, p. 135-143
Showing items related by title, author, creator and subject.
Two different epidemiological scenarios of border disease in the populations of Pyrenean chamois (Rupicapra p. pyrenaica) after the first disease outbreaks Fernández Sirera, Laura; Cabezón Ponsoda, Óscar; Allepuz Palau, Alberto; Rosell Bellsola, Rosa; Riquelme Guerrero, Cristina; Serrano Ferrón, Emmanuel; Lavín González, Santiago; Marco Sánchez, Ignasi (Public Library of Science, 2012)Since 2001 several outbreaks of a new disease associated with Border disease virus (BDV) infection have caused important declines in Pyrenean chamois (Rupicapra pyrenaica) populations in the Pyrenees. The goal of this ...
Predicting cardiovascular disease morbidity and mortality in chronic kidney disease in Spain. The rationale and design of NEFRONA: a prospective, multicenter, observational cohort study Junyent, Mireia; Martínez Alonso, Montserrat; Borràs, Mercè; Coll, Blai; Valdivielso Revilla, José Manuel; Vidal, Teresa; Sarró, Felipe; Roig, Jordi; Craver Hospital, Lourdes; Fernández i Giráldez, Elvira (BioMed Central, 2010)Background: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in patients with chronic kidney disease (CKD). Cardiovascular risk assessment in this population is hampered by the failure of ...
Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease Anguiano, Lidia; Riera, Marta; Pascual, Julio; Valdivielso Revilla, José Manuel; Barrios, Clara; Betriu i Bars, M. Àngels; Mojal, Sergi; Fernández i Giráldez, Elvira; Soler, María José (Oxford University Press, 2015)